Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23727832 | 1.00 | TRPV1 (0.56) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL23727830 | 1.00 | TRPV1 (0.56) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL8515991 | 0.93 | TAAR1 (0.51) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL8515989 | 0.93 | TAAR1 (0.51) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL16289717 | 0.88 | TRPV1 (0.64) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL16289982 | 0.88 | TRPV1 (0.64) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL16289718 | 0.88 | TRPV1 (0.64) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL16288652 | 0.88 | TRPV1 (0.64) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL597782 | 0.88 | TRPV1 (0.64) | TRPV1MAPTRXFP1TAAR1HDAC1 | |
| SCHEMBL16288651 | 0.88 | TRPV1 (0.64) | TRPV1MAPTRXFP1TAAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION,INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | PSMB10, PSMB1, PSMB5 | TRPV1 3705/4885MAPT 2616/4885RXFP1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.